Newsroom & Publications

Welcome to Cytogel’s online Newsroom, offering a range of information, publications and background to the media. As a member of the media, you are invited to contact Kimberly Weinrick, Head of Communications.

About Cytogel 

Cytogel Pharma is a clinical stage biopharmaceutical company dedicated to developing and bringing to market innovative products to treat pain, safely and effectively. Founded in 2006, Cytogel has created a patent portfolio which includes a number of compositions with attractive pharmaceutical properties. Its lead compound, CYT-1010, is entering Phase 2 clinical development, following a successful Phase 1 study in humans.

As the first member of a new class of drugs, the endomorphins, CYT-1010 is a breakthrough pain medicine which in pre-clinical trials has shown to have substantially reduced addiction potential and significantly less risk of respiratory depression than has been experienced with traditional pain treatments. Cytogel believes CYT-1010 offers a transformational alternative drug treatment in pain management for the benefit and safety of patients.

Additionally, Cytogel has two patented technologies for enhancing the delivery of drugs and improving pharmacokinetics.  These technologies are biocompatible hydrogels and polymer-based gels that have potential application for a variety of uses, including therapeutic proteins and improved drug eluting coatings on medical devices.

Press Kit:

Cytogel Mission
Cytogel History and Background
CEO Bio - C. Dean Maglaris

Media Contact:
Kimberly Weinrick


+ Expand all

News & Publications:

+ Expand all

FAQs - Frequently Asked Questions